Although the dysregulated function of HDAC inhibitors may have an important role in malignant transformation and in the response to cancer treatment, the in vivo mechanisms behind the effects of HDAC inhibitors in CTCL are largely unknown. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.